Spontaneous quinolone resistance in the zoonotic serovar of Vibrio vulnificus. by Roig Molina, Francisco José et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Apr. 2009, p. 2577–2580 Vol. 75, No. 8
0099-2240/09/$08.000 doi:10.1128/AEM.02921-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Spontaneous Quinolone Resistance in the Zoonotic Serovar of
Vibrio vulnificus†
Francisco J. Roig, A. Llorens, B. Fouz, and C. Amaro*
Departamento de Microbiología, Facultad de Biología, Universidad de Valencia, Valencia, Spain
Received 22 December 2008/Accepted 4 February 2009
This work demonstrates that Vibrio vulnificus biotype 2, serovar E, an eel pathogen able to infect humans, can
become resistant to quinolone by specific mutations in gyrA (substitution of isoleucine for serine at position 83)
and to some fluoroquinolones by additional mutations in parC (substitution of lysine for serine at position 85).
Thus, to avoid the selection of resistant strains that are potentially pathogenic for humans, antibiotics other
than quinolones must be used to treat vibriosis on farms.
Vibrio vulnificus is an aquatic bacterium from warm and trop-
ical ecosystems that causes vibriosis in humans and fish (http:
//www.cdc.gov/nczved/dfbmd/disease_listing/vibriov_gi.html) (33).
The species is heterogeneous and has been subdivided into
three biotypes and more than eight serovars (6, 15, 33; our
unpublished results). While biotypes 1 and 3 are innocuous for
fish, biotype 2 can infect nonimmune fish, mainly eels, by
colonizing the gills, invading the bloodstream, and causing
death by septicemia (23). The disease is rapidly transmitted
through water and can result in significant economic losses to
fish farmers. Surviving eels are immune to the disease and can
act as carriers, transmitting vibriosis between farms. Interest-
ingly, biotype 2 isolates belonging to serovar E have been
isolated from human infections, suggesting that serovar E is
zoonotic (2). This serovar is also the most virulent for fish and
has been responsible for the closure of several farms due to
massive losses of fish. A vaccine, named Vulnivaccine, has
been developed from serovar E isolates and has been success-
fully tested in the field (14). Although the vaccine provides fish
with long-term protection from vibriosis, at present its use is
restricted to Spain. For this reason, in many fish farms around
the world, vibriosis is treated with antibiotics, which are usually
added to the food or water.
Quinolones are considered the most effective antibiotics
against human and fish vibriosis (19, 21, 31). These antibiotics
can persist for a long time in the environment (20), which
could favor the emergence of resistant strains under selective
pressure. In fact, spontaneous resistances to quinolones by
chromosomal mutations have been described for some gram-
negative bacteria (10, 11, 17, 24, 25, 26). Therefore, improper
antibiotic treatment of eel vibriosis or inadequate residue elim-
ination at farms could favor the emergence of human-patho-
genic serovar E strains resistant to quinolones by spontaneous
mutations. Thus, the main objective of the present work was to
find out if the zoonotic serovar of biotype 2 can become quin-
olone resistant under selective pressure and determine the
molecular basis of this resistance.
Very few reports on resistance to antibiotics in V. vulnificus
have been published; most of them have been performed with
biotype 1 isolates. For this reason, the first task of this study
was to determine the antibiotic resistance patterns in a wide
collection of V. vulnificus strains belonging to the three bio-
types that had been isolated worldwide from different sources
(see Table S1 in the supplemental material). Isolates were
screened for antimicrobial susceptibility to the antibiotics
listed in Table S1 in the supplemental material by the agar
diffusion disk procedure of Bauer et al. (5), according to the
standard guideline (9). The resistance pattern found for each
isolate is shown in Table S1 in the supplemental material. Less
than 14% of isolates were sensitive to all the antibiotics tested,
and more than 65% were resistant to more than one antibiotic,
irrespective of their biotypes or serovars. The most frequent
resistances were to ampicillin-sulbactam (SAM; 65.6% of the
strains) and nitrofurantoin (F; 60.8% of the strains), and the
least frequent were to tetracycline (12%) and oxytetracycline
(8%). In addition, 15% of the strains were resistant to nalidixic
acid (NAL) and oxolinic acid (OA), and 75% of these strains
came from fish farms (see Table S1 in the supplemental ma-
terial). Thus, high percentages of strains of the three biotypes
were shown to be resistant to one or more antibiotics, with
percentages similar to those found in nonbiotyped environ-
mental V. vulnificus isolates from Asia and North America (4,
27, 34). In those studies, resistance to antibiotics could not be
related to human contamination. However, the percentage of
quinolone-resistant strains found in our study is higher than
that reported in other ones, probably due to the inclusion of
fish farm isolates, where the majority of quinolone-resistant
strains were concentrated. This fact suggests that quinolone
resistance could be related to human contamination due to the
improper use of these drugs in therapy against fish diseases, as
has been previously suggested (18, 20). Although no specific
resistance pattern was associated with particular biotypes or
serovars, we found certain differences in resistance distribu-
tion, as shown in Table 1. In this respect, biotype 3 displayed
the narrowest spectrum of resistances and biotype 1 the widest.
The latter biotype encompassed the highest number of strains
with multiresistance (see Table S1 in the supplemental mate-
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rial). Within biotype 2, there were differences among serovars,
with quinolone resistance being restricted to the zoonotic ser-
ovar (Table 1).
The origin of resistance to quinolones in the zoonotic sero-
var was further investigated. To this end, spontaneous mutants
of sensitive strains were selected from colonies growing within
the inhibition halo around OA or NAL disks. Two strains
(strain CG100 of biotype 1 and strain CECT 4604 of biotype 2,
serovar E) developed isolated colonies within the inhibition
zone. These colonies were purified, and maintenance of resis-
tance was confirmed by serial incubations on medium without
antibiotics. Using the disk diffusion method, CG100 was shown
to be resistant to SAM and F and CECT 4604 to F (see Table
S1 in the supplemental material). The MICs for OA, NAL,
flumequine (UB), and ciprofloxacin (CIP) were determined by
using the microplate assay according to the recommendations
of the Clinical and Laboratory Standards Institute and the
European Committee for Antimicrobial Susceptibility Testing
of the European Society of Clinical Microbiology and Infec-
tious Diseases (8, 12) and interpreted according to the Euro-
pean Committee for Antimicrobial Susceptibility Testing of
the European Society of Clinical Microbiology and Infectious
Diseases (13). The MICs for OA and NAL and for the fluo-
roquinolones UB and CIP exhibited by the mutants and their
counterparts are shown in Table 2. The inhibition zone diam-
eters correlated well with MICs (data not shown). Mutants
FR1, FR2, FR3, and FR4 were resistant to NAL and sensitive
to the remaining quinolones, although they showed higher
resistances than their parental strains (Table 2). Thus, these
four mutants showed increases of 32- to 128-fold for NAL
MICs, 4- to 8-fold for UB MICs, and 16-fold for CIP MICs
(Table 2). The fifth mutant, FR5, was resistant to the two
tested quinolones and to UB, a narrow-spectrum fluoroquin-
olone. This mutant, although sensitive to CIP, multiplied its
MIC for this drug by 128 with respect to the parental strain
(Table 2).
For other gram-negative pathogens, quinolone resistance
relies on spontaneous mutations in the gyrA, gyrB, parC, and
parE genes that occur in a specific region of the protein known
as the quinolone resistance-determining region (QRDR) (1,
11, 17, 24, 25, 26, 28). To test the hypothesis that mutations in
these genes could also produce quinolone resistance in V.
vulnificus, the QRDRs of these genes were sequenced in the
naturally resistant strains and in the two sensitive strains that
had developed resistances by selective pressure in vitro. The
genomic DNA was extracted (3), and the QRDRs of gyrA,
gyrB, parE, and parC were amplified using the primers shown in
Table 3, which were designed from the published genomes of
biotype 1 strains YJ016 and CMCP6 (7, 22). PCR products of
the predicted size were sequenced in an ABI 3730 sequencer
(Applied Biosystems). Analysis of the QRDR sequences for
gyrA, gyrB, parC, and parE of the mutants and the naturally
resistant strains revealed that all naturally resistant strains,
except one, shared a specific mutation at nucleotide position
248 with the laboratory-induced mutants (Table 2). This mu-
tation gave rise to a change from serine to isoleucine at amino
acid position 83. The exception was a mutation in the adjacent
nucleotide that gave rise to a substitution of arginine for serine
at the same amino acid position (Table 2). All the isolates that
were resistant to the quinolone NAL had a unique mutation in
the gyrA gene, irrespective of whether resistance was acquired
naturally or in the laboratory (Table 2). This result strongly
suggests that a point mutation in gyrA that gives rise to a
change in nucleotide position 83 can confer resistance to NAL
in V. vulnificus biotypes 1 and 2 and that this mutation could be
produced by selective pressure under natural conditions. gyrA
mutations consisting of a change from serine 83 to isoleucine
have also been described in isolates of Aeromonas from water
(17) and in diseased fish isolates of Vibrio anguillarum (26).
Similarly, replacement of serine by arginine at amino acid
position 83 in diseased fish isolates of Yersinia ruckeri (16)
suggests that this mechanism of quinolone resistance is wide-
spread among gram-negative pathogens. In all cases, these
single mutations were also related to increased resistance to
other quinolones (OA) and fluoroquinolones (UB and CIP)
(Table 2), although the mutants remained sensitive according
to the standards of the Clinical and Laboratory Standards
Institute and the European Committee for Antimicrobial Sus-
ceptibility Testing of the European Society of Clinical Micro-
biology and Infectious Diseases (9, 13). A total of 50% of the
naturally resistant strains, all of them of biotype 1, showed
additional mutations that affected parC (a change in amino
acid position 113) or gyrB (changes in amino acids at positions
425 and 438) (Table 2). These strains exhibited higher MICs
for OA and fluoroquinolones (Table 2), although they were
still sensitive to these drugs (9, 13). Finally, one isolate of
biotype 2, serovar E, which was naturally resistant to quino-
lones and UB, showed a mutation in parC that gave rise to a
TABLE 1. Percentage of resistant strains distributed by biotypes and serovars
V. vulnificus No. ofisolates
Resistance distribution (%) for indicated antibiotica
SAM CTX E NAL F OT OA SXT-TMP TE
Biotype 1 49 75.5 24.5 14.3 30.6 83.7 8.2 30.6 28.6 8.2
Biotype 2 (whole) 72 58.3 13.9 12.5 4.2 47.2 9.7 4.2 4.2 13.9
Biotype 2
Serovar E 36 30.3 12.1 3 9.1 27.3 15.2 9.1 3 21.2
Serovar A 23 100 9.1 18.2 0 77.3 0 0 9.1 4.6
Nontypeable 8 29 14.3 25 0 57.1 14.3 0 0 14.3
Serovar I 5 100 20 20 0 20 20 0 0 0
Biotype 3 5 100 0 20 0 80 0 0 0 20
a CTX, cefotaxime; E, erythromycin; OT, oxytetracycline; SXT-TMP, sulfamethoxazole-trimethoprim; TE, tetracycline.
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substitution of leucine for serine at amino acid position 85
(Table 2). This mutation was shared only with the laboratory-
induced mutant, also a biotype 2, serovar E mutant, which was
resistant to the fluoroquinolone UB. The same mutation in
parC had been previously described in diseased fish isolates of
V. anguillarum that were highly resistant to quinolones (28),
but this had not been related to fluoroquinolone resistance in
Vibrio spp. nor in other gram-negative bacteria. These results
strongly suggest that resistance to fluoroquinolones in V. vulni-
ficus is related to specific mutations in gyrA and parC and that
mutations in different positions for parC or in gyrB could con-
tribute to increased resistance to quinolones and fluoroquino-
lones. Our results also agree with previous studies confirming
that the acquisition of higher quinolone resistance is more
probable when arising from a gyrA parC double mutation than
from a gyrA gyrB double mutation (29).
Finally, the evolutionary history for each protein was in-
ferred from previously published DNA sequences of the whole
genes from different Vibrio species after multiple sequence
alignment with MEGA4 software (32) by applying the neigh-
bor-joining method (30) with the Poisson correction (35). The
distance tree for each whole protein showed a topology similar
to the phylogenetic tree based on 16S rRNA analysis, with the
two isolates of V. vulnificus forming a single group, closely
related to Vibrio parahaemolyticus, Vibrio cholerae, V. anguilla-
rum, and Vibrio harveyi (see Fig. S1A in the supplemental
material). A second analysis was performed with the QRDR
sequences of the different mutants and isolates of V. vulnificus
(GenBank accession numbers FJ379836 to FJ379927) to infer
the intraspecies relationships (see Fig. S1B in the supplemen-
tal material). This analysis showed that QRDRs of gyrA, gyrB,
parC, and parE were highly homogeneous within V. vulnificus.
In summary, the zoonotic serovar of V. vulnificus can mutate
spontaneously to gain quinolone resistance, under selective
pressure in vitro, due to specific mutations in gyrA that involve
a substitution of isoleucine for serine at amino acid position 83.
This mutation appears in biotype 2, serovar E diseased-fish
isolates and biotype 1 strains, mostly recovered from fish
farms. An additional mutation in parC, resulting in a substitu-
tion of lysine for serine at amino acid position 85, seems to
endow partial fluoroquinolone resistance on biotype 2, serovar
E strains. This kind of double mutation is present in diseased-
fish isolates of the zoonotic serovar but not in resistant biotype
1 isolates, which show different mutations in gyrB or in parC
that increase their resistance levels but do not make the strains
resistant to fluoroquinolones. Thus, antibiotics other than
quinolones should be used at fish farms to prevent the emer-
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TABLE 3. Oligonucleotides used in this study
Primer Sequence Annealingtemp (°C)
Size
(bp)
GyrAF GGCAACGACTGGAATAAACC 55.8 416
GyrAR CAGCCATCAATCACTTCCGTC
ParCF CGCAAGTTCACCGAAGATGC 56.6 411
ParCR GGCATCCGCAACTTCACG
GyrBF CGACTTCTGGTGACGATGCG 57.4 642
GyrBR GACCGATACCACAACCTAGTG
ParEF GCCAGGTAAGTTGACCGATTG 56.8 512
ParER CACCCAGACCTTTGAATCGTTG
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gence and spread of quinolone resistances, especially to CIP, a
drug widely recommended for human vibriosis treatment.
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